Get the Stockscreener App
1.77
1.14%
0.02
After Hours:
1.77
Iterum Therapeutics Plc Stock (ITRM) Forecast
The Iterum Therapeutics Plc (ITRM) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $40.45, representing a +2,185% increase from the current price of $1.77. The highest analyst price target is $46.42, and the lowest is $34.47.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ITRM Price Target
Average 47.17
(+2,565% Upside)
Is Iterum Therapeutics Plc (ITRM) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 46.55 | Neutral |
| STOCH(9,6) | 6.6104 | Buy |
| STOCHRSI(14) | 7.3151 | Buy |
| MACD(12,26) | 0.0349 | Sell |
| ADX(14) | 32.13 | Sell |
| William %R | -89.61 | Buy |
| CCI(14) | -56.31 | Neutral |
Buy: 3
Sell: 2
Neutral: 2
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.986
Sell
|
1.9148
Sell
|
| MA20 |
2.116
Sell
|
1.9413
Sell
|
| MA50 |
1.6288
Buy
|
1.724
Buy
|
| MA100 |
1.3705
Buy
|
1.5343
Buy
|
| MA200 |
1.4025
Buy
|
1.412
Buy
|
Buy: 6
Sell: 4
Neutral: 0
Summary: Buy
According to our latest analysis, ITRM could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 6 signaling Sell signals and 2 Neutral signals. This might be a good time to open fresh positions on ITRM, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 46.55 indicates that ITRM is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 6.6104 indicates that ITRM is oversold. This indicates that ITRM price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 7.3151 indicates that ITRM is oversold. This suggests that ITRM price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 32.13 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -56.31 indicates that ITRM is still oversold but not to an extreme extent.
Long-term ITRM price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Iterum Therapeutics Plc financial reports and earnings history, Iterum Therapeutics Plc (ITRM) stock could reach $100.51 by 2030, $71.32 by 2040 and $229.08 by 2050. See the projected annual prices until 2050 of the Iterum Therapeutics Plc stock below:
- Iterum Therapeutics Plc (ITRM) is expected to reach an average price of $20.26 in 2035, with a high prediction of $24.64 and a low estimate of $21.23. This indicates an $1,045% rise from the last recorded price of $1.77.
- Iterum Therapeutics Plc (ITRM) stock is projected to chart a bullish course in 2040, with an average price target of $68.05, representing an $3,745% surge from its current level. The forecast ranges from a conservative $68.22 to a sky-high $71.32.
- Our analysts predict Iterum Therapeutics Plc (ITRM) to jump 7,598% by 2045, soaring from $136.47 to an average price of $136.26, potentially reaching $139.87. While $136.47 is the low estimate, the potential upside is significant.
- Iterum Therapeutics Plc (ITRM) stock is expected to climb by 2050, reaching an average of $223.56, a $12,530% jump from its current level. However, a wide range of estimates exists, with high and low targets of $229.08 and $225.36, respectively, highlighting the market's uncertainty.
Iterum Therapeutics Plc Stock (ITRM) Year by Year Forecast
Iterum Therapeutics Plc Stock (ITRM) Price Forecast for 2025
Iterum Therapeutics Plc Stock (ITRM) is expected to reach an average price of $47.17 in 2025, with a high prediction of $66.69 and a low estimate of $27.65. This indicates an +2,565% rise from the last recorded price of $1.77.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $24.68 | $34.47 | $46.42 | +1,294% |
| February, 2025 | $54.19 | $31.38 | $47.74 | +2,962% |
| March, 2025 | $51.60 | $51.40 | $47.84 | +2,815% |
| April, 2025 | $45.22 | $47.02 | $54.74 | +2,455% |
| May, 2025 | $45.78 | $48.02 | $43.82 | +2,486% |
| June, 2025 | $31.49 | $31.29 | $27.13 | +1,679% |
| July, 2025 | $58.71 | $27.65 | $57.36 | +3,217% |
| August, 2025 | $62.27 | $59.34 | $61.87 | +3,418% |
| September, 2025 | $63.13 | $63.63 | $62.08 | +3,467% |
| October, 2025 | $67.92 | $65.48 | $65.86 | +3,737% |
| November, 2025 | $59.71 | $66.26 | $66.69 | +3,273% |
| December, 2025 | $66.62 | $61.24 | $65.78 | +3,664% |
Iterum Therapeutics Plc Stock (ITRM) Price Forecast for 2026
The predicted value for Iterum Therapeutics Plc (ITRM) in 2026 is set at an average of $46.48. Estimates vary from a peak of $65.59 to a trough of $27.36, indicating an +2,526% surge from the present price of $1.77.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $60.90 | $64.24 | $65.59 | +3,341% |
| February, 2026 | $57.52 | $58.05 | $60.44 | +3,150% |
| March, 2026 | $51.41 | $53.66 | $54.96 | +2,805% |
| April, 2026 | $36.78 | $38.58 | $44.52 | +1,978% |
| May, 2026 | $41.39 | $43.04 | $40.84 | +2,238% |
| June, 2026 | $45.25 | $44.10 | $42.96 | +2,457% |
| July, 2026 | $47.57 | $46.91 | $46.82 | +2,587% |
| August, 2026 | $33.73 | $37.92 | $45.27 | +1,806% |
| September, 2026 | $40.55 | $27.36 | $37.85 | +2,191% |
| October, 2026 | $47.17 | $43.36 | $46.21 | +2,565% |
| November, 2026 | $47.37 | $47.67 | $47.79 | +2,576% |
| December, 2026 | $47.31 | $47.17 | $46.73 | +2,573% |
Iterum Therapeutics Plc Stock (ITRM) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Iterum Therapeutics Plc (ITRM) is $40.41, with a high forecast of $46.18 and a low forecast of $34.65. This indicates an +2,183% increase from the last price of $1.77.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $46.47 | $46.48 | $46.18 | +2,525% |
| February, 2027 | $45.48 | $45.01 | $44.46 | +2,470% |
| March, 2027 | $44.05 | $44.48 | $44.91 | +2,389% |
| April, 2027 | $43.94 | $44.09 | $43.48 | +2,382% |
| May, 2027 | $42.32 | $43.26 | $43.86 | +2,291% |
| June, 2027 | $41.15 | $41.27 | $41.57 | +2,225% |
| July, 2027 | $39.95 | $39.89 | $40.45 | +2,157% |
| August, 2027 | $39.68 | $39.81 | $39.41 | +2,142% |
| September, 2027 | $38.80 | $39.16 | $39.17 | +2,092% |
| October, 2027 | $37.69 | $37.96 | $38.21 | +2,030% |
| November, 2027 | $35.78 | $36.36 | $37.20 | +1,921% |
| December, 2027 | $33.74 | $34.65 | $34.59 | +1,806% |
Iterum Therapeutics Plc Stock (ITRM) Price Forecast for 2028
In 2028, Iterum Therapeutics Plc (ITRM) is projected to reach an average price of $26.30, with a high projection of $34.00 and a low estimate of $18.60. This indicates an +1,386% rise from the last price of $1.77.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $33.82 | $33.84 | $34.00 | +1,811% |
| February, 2028 | $33.25 | $33.28 | $33.49 | +1,779% |
| March, 2028 | $31.45 | $31.49 | $32.47 | +1,677% |
| April, 2028 | $30.42 | $30.54 | $31.06 | +1,619% |
| May, 2028 | $29.19 | $29.23 | $30.04 | +1,549% |
| June, 2028 | $27.45 | $27.53 | $28.79 | +1,451% |
| July, 2028 | $25.96 | $26.02 | $27.05 | +1,367% |
| August, 2028 | $24.54 | $24.54 | $25.57 | +1,287% |
| September, 2028 | $23.15 | $23.20 | $23.77 | +1,208% |
| October, 2028 | $21.61 | $21.68 | $22.53 | +1,121% |
| November, 2028 | $19.78 | $19.84 | $21.18 | +1,018% |
| December, 2028 | $18.54 | $18.60 | $19.36 | +947.22% |
Iterum Therapeutics Plc Stock (ITRM) Price Forecast for 2029
The 2029 price forecast for Iterum Therapeutics Plc Stock (ITRM) is $45.29 on average, with a high prediction of $90.12 and a low estimate of $0.4629. This represents an +2,459% increase from the previous price of $1.77.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $16.81 | $16.85 | $18.08 | +849.78% |
| February, 2029 | $15.59 | $15.61 | $16.45 | +780.99% |
| March, 2029 | $14.32 | $14.35 | $15.22 | +708.80% |
| April, 2029 | $12.95 | $13.01 | $13.94 | +631.53% |
| May, 2029 | $11.18 | $11.26 | $12.51 | +531.84% |
| June, 2029 | $8.4658 | $8.7571 | $9.8266 | +378.30% |
| July, 2029 | $7.2282 | $7.8082 | $8.0389 | +308.37% |
| August, 2029 | $5.9236 | $6.0135 | $6.6512 | +234.67% |
| September, 2029 | $4.8059 | $4.8562 | $5.4567 | +171.52% |
| October, 2029 | $2.7413 | $2.8013 | $4.3822 | +54.88% |
| November, 2029 | $1.5236 | $1.5336 | $2.3244 | -13.92% |
| December, 2029 | $101.97 | $0.4629 | $90.12 | +5,661% |
Iterum Therapeutics Plc Stock (ITRM) Price Forecast for 2030
Iterum Therapeutics Plc Stock (ITRM) is expected to reach an average price of $122.19 in 2030, with a high forecast of $148.17 and a low forecast of $96.21. This signifies an +6,803% surge from the last price of $1.77.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $92.95 | $101.28 | $100.51 | +5,151% |
| February, 2030 | $101.30 | $106.38 | $99.63 | +5,623% |
| March, 2030 | $99.40 | $100.75 | $99.38 | +5,516% |
| April, 2030 | $101.56 | $96.21 | $97.82 | +5,638% |
| May, 2030 | $105.31 | $99.16 | $101.26 | +5,849% |
| June, 2030 | $136.88 | $122.16 | $131.48 | +7,633% |
| July, 2030 | $156.51 | $147.94 | $147.15 | +8,742% |
| August, 2030 | $142.96 | $142.13 | $148.17 | +7,977% |
| September, 2030 | $119.76 | $121.41 | $111.75 | +6,666% |
| October, 2030 | $137.05 | $130.92 | $136.73 | +7,643% |
| November, 2030 | $145.02 | $141.06 | $136.77 | +8,093% |
| December, 2030 | $132.04 | $132.88 | $141.30 | +7,360% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):